Atherothrombosis and oxidative stress: the connection and correlation in diabetes

References

• Tracy RP. Thrombin, inflammation and cardiovascular disease: An epidemiologic perspective. Chest 2003; 124 ( Suppl): 49S-57S.
   Google Scholar
• Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. Circulation 1995; 91: 284–290.
   PubMed Web of Science ®Google Scholar
• Hon i Y, Gabazza EC, Yano Y et al. Insulin resistance is associatedwith increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660–665.
   PubMed Web of Science ®Google Scholar
• Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–1801.
   PubMed Web of Science ®Google Scholar
• Yano Y, Kitagawa N, Gabazza EC et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88: 736–741.
   PubMed Web of Science ®Google Scholar
• Harmanci A, Kandemir N, Dagdelen S et al. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in type 1diabetes: evidence for normal fibrinolytic state. J Dia betComplications 2006; 20: 40–44.
   PubMed Web of Science ®Google Scholar
• Antovic JP, Yngen M, Ostenson CG et al. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis 2003; 14: 551–556.
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075–1081.
   PubMed Web of Science ®Google Scholar
• Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004; 27: 2178–2183.
   PubMed Web of Science ®Google Scholar
• Solans R, Motta C, Sold R et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: Evidence of free radical-mediated injury. Arthr Rheum 2000; 43: 894–900.
   PubMed Web of Science ®Google Scholar
• Church TS, Lavie CJ, Milani RV, Kirby GS. Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease. Am Heart J 2002; 143: 349–355.
   PubMed Web of Science ®Google Scholar
• Krupinski J, Turu MM, Font MA et al. Increased tissue factor, MMP-8, and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis. Vasc Health Risk Manage 2007; 3: 405–412.
   PubMedGoogle Scholar
• Spronk HM, van der Voort D, Ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J2004; 2: 12.
   Google Scholar
• Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381–1478.
   PubMed Web of Science ®Google Scholar
• Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 2001; 54: 176–186.
   PubMed Web of Science ®Google Scholar
• Day SM, Duquaine D, Mundada LV et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation 2003; 107: 2601–2606.
   PubMed Web of Science ®Google Scholar
• Lowe G. Can haematology laboratories predict thrombosis? Clin Lab Haematol 2001; 23: 335–354.
   PubMedGoogle Scholar
• Yang ZC, Xia K, Wang L et al. Asymmetric dimethylarginine reduced erythrocyte deformability in streptozotocin-induced diabetic rat. Microvasc Res 2007; 73: 131–136.
   PubMed Web of Science ®Google Scholar
• New Zealand Guidelines Group. The assessment and management ofcardiovascularrisk. 2005. www.nzgg.org.nz/guidelines/0101/050624_cvd_resource_(final)_v5_for_printing_2.pdf [ Accessed 2 July 2008].
   Google Scholar
• Better Health Channel. Body mass index (BMI). 2006. www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/body_m ass_index_(bmi) [Accessed 14 February 2007].
   Google Scholar
• Drug and Alcohol Office. Drinking guidelines and standard drink. 2006. http://www.dao.health.wa.gov.au/structure/prevention/drinkingguidelinesstandarddrinks/tabid/93/default.aspx?pageco ntentmode= [Accessed 4 January 2007].
   Google Scholar
• Banerjee M, Cruickshank JK. Prediabetes: is the term useful? Br J Diabetes Vasc Dis 2004; 4: 221–225.
   Google Scholar
• Tirosh A, Shai I, Tekes-Manova D et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454–1462.
   PubMed Web of Science ®Google Scholar
• Richards R, Roberts T, McGregor N, Dunstan R, Butt H. Erythrocyte antioxidant systems protect cultured endothelial cells against oxidant damage. Biochem Mol Biol Int 1998; 46: 857–865.
   PubMedGoogle Scholar
• Kirkwood BR, Sterne JAC. Essential Medical Statistics, 2nd edn. Oxford: Blackwell Science, 2003; 109-349.
   Google Scholar
• Lowe G, Yarnell J, Rumley A, Bainton D, Sweetnam P. C-Reactive protein, fibrin D-dimer, and incident of ischemic heart disease in the Speedwell Study. Arterioscler Thromb Vasc Biol 2001; 21: 603–610.
   PubMed Web of Science ®Google Scholar
• Nwose EU, Jelinek HF, Richards RS, Kerr PG. Changes in oxidative stress markers during the progression of diabetes mellitus [Conference abstract]. Free Radic Res 2006; 40 (Suppl 1): 138.
   Google Scholar
• Nwose EU, Jelinek HF, Richards RS, Kerr PG. Changes in the erythrocyte glutathione concentration in the course of diabetes mellitus. Redox Report 2006; 11: 99–105.
   PubMed Web of Science ®Google Scholar
• Nwose EU, Richards RS, Jelinek HF, Kerr PG. D-Dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications. Pathology 2007; 39: 252–257.
   PubMed Web of Science ®Google Scholar
• Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997; 96: 168–173.
   PubMed Web of Science ®Google Scholar
• Lowe GDO, Rumley A, McMahon AD, Ford I, O'Reilly DJ, Packard CJ, Prevention Study Group. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529–1534.
   PubMed Web of Science ®Google Scholar
• Lowe GD, Rumley A, Sweetnam PM, Yarnell JW, Rumley J. Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost 2001; 86: 822–827.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109 (Suppl 1): 1V6-IV19.
   Google Scholar
• Aboud M, Low J, Bonar R et al. QAP D-dimer questionnaire report. Australia: RCPA Haematology QAP, 2003.
   Google Scholar
• Morse M. Establishing a normal range for D-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis. J Thromb Haemost 2004; 2: 1202–1204.
   PubMed Web of Science ®Google Scholar
• Rathbun SW, Whitsett TL, Vesely SK, Raskob GE. Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med 2004; 141: 839–845.
   PubMed Web of Science ®Google Scholar
• Palareti G, Cosmi B, Legnani C et al. D-Dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780–1789.
   PubMed Web of Science ®Google Scholar
• Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 2002; 51: 471–476.
   PubMed Web of Science ®Google Scholar